- Home
- CAAP vs FOLD Comparison
CAAP vs FOLD Comparison
Compare CAAP & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAAP
- FOLD
- Stock Information
- Founded
- CAAP 1998
- FOLD 2002
- Country
- CAAP Luxembourg
- FOLD United States
- Employees
- CAAP N/A
- FOLD 499
- Industry
- CAAP Aerospace
- FOLD Biotechnology: Pharmaceutical Preparations
- Sector
- CAAP Consumer Discretionary
- FOLD Health Care
- Exchange
- CAAP Nasdaq
- FOLD Nasdaq
- Market Cap
- CAAP 2.9B
- FOLD 2.5B
- IPO Year
- CAAP 2018
- FOLD 2007
- Fundamental
- Price
- CAAP $17.91
- FOLD $8.57
- Analyst Decision
- CAAP Strong Buy
- FOLD Strong Buy
- Analyst Count
- CAAP 2
- FOLD 9
- Target Price
- CAAP $24.60
- FOLD $26.44
- AVG Volume (30 Days)
- CAAP 262.7K
- FOLD 5.3M
- Earning Date
- CAAP 11-19-2025
- FOLD 11-05-2025
- Dividend Yield
- CAAP N/A
- FOLD N/A
- EPS Growth
- CAAP N/A
- FOLD N/A
- EPS
- CAAP 0.93
- FOLD N/A
- Revenue
- CAAP $1,873,095,000.00
- FOLD $571,160,000.00
- Revenue This Year
- CAAP $4.43
- FOLD $21.04
- Revenue Next Year
- CAAP $10.96
- FOLD $21.34
- P/E Ratio
- CAAP $19.33
- FOLD N/A
- Revenue Growth
- CAAP 26.88
- FOLD 25.35
- 52 Week Low
- CAAP $15.01
- FOLD $5.51
- 52 Week High
- CAAP $22.85
- FOLD $12.65
- Technical
- Relative Strength Index (RSI)
- CAAP 43.82
- FOLD 59.52
- Support Level
- CAAP $17.51
- FOLD $7.87
- Resistance Level
- CAAP $18.30
- FOLD $8.49
- Average True Range (ATR)
- CAAP 0.50
- FOLD 0.33
- MACD
- CAAP 0.12
- FOLD -0.01
- Stochastic Oscillator
- CAAP 64.89
- FOLD 91.72
About CAAP Corporacion America Airports SA
Corporacion America Airports SA acquires, develops, and operates airport concessions. Its operating segments are geographically divided into Argentina, Italy, Brazil, Uruguay, Ecuador, and Armenia. The company generates a majority of its revenue from the Argentina segment. The firm's revenue is categorized into Aeronautical Revenue, Non-Aeronautical Revenue, Commercial Revenue, Construction Service Revenue, and Other Revenue.
About FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.